Advanced vulvar apocrine carcinoma expressing estrogen receptors that responds to tamoxifen therapy

Future Oncol. 2012 Sep;8(9):1199-203. doi: 10.2217/fon.12.94.

Abstract

Primary vulvar carcinoma is rare and thought to arise from either anogenital mammary-like glands or native apocrine sweat glands. The diagnosis is predominantly based on tumor morphology with supportive evidence from immunohistochemical staining and exclusion of a primary breast carcinoma. The primary modality of treatment is surgery, while optimal managment of advanced disease is unclear. We present the case of a lady who had metastatic recurrent apocrine carcinoma expressing estrogen receptors, who had a complete response assessed by PET-CT scanning after 7 months of tamoxifen therapy. The report includes a discussion of the histological diagnosis and assessment of response to treatment by PET-CT scanning.

Publication types

  • Case Reports

MeSH terms

  • Aged
  • Antineoplastic Agents, Hormonal / therapeutic use*
  • Carcinoma / diagnostic imaging*
  • Carcinoma / drug therapy
  • Carcinoma / metabolism
  • Carcinoma / secondary
  • Female
  • Humans
  • Neoplasms, Hormone-Dependent / diagnostic imaging*
  • Neoplasms, Hormone-Dependent / drug therapy
  • Neoplasms, Hormone-Dependent / metabolism
  • Neoplasms, Hormone-Dependent / pathology
  • Radiography
  • Receptors, Estrogen / metabolism*
  • Skin Neoplasms / diagnostic imaging*
  • Skin Neoplasms / drug therapy
  • Skin Neoplasms / metabolism
  • Skin Neoplasms / secondary
  • Tamoxifen / therapeutic use*
  • Treatment Outcome
  • Vulvar Neoplasms / diagnostic imaging*
  • Vulvar Neoplasms / drug therapy
  • Vulvar Neoplasms / metabolism
  • Vulvar Neoplasms / pathology

Substances

  • Antineoplastic Agents, Hormonal
  • Receptors, Estrogen
  • Tamoxifen